Agenus (AGEN) Competitors $5.93 +0.42 (+7.62%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$6.01 +0.08 (+1.35%) As of 07/3/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGEN vs. MYGN, ZBIO, EBS, LXRX, RIGL, CBIO, XOMA, VNDA, VSTM, and CDXSShould you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Myriad Genetics (MYGN), Zenas BioPharma (ZBIO), Emergent Biosolutions (EBS), Lexicon Pharmaceuticals (LXRX), Rigel Pharmaceuticals (RIGL), Crescent Biopharma (CBIO), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), and Codexis (CDXS). These companies are all part of the "biotechnology" industry. Agenus vs. Its Competitors Myriad Genetics Zenas BioPharma Emergent Biosolutions Lexicon Pharmaceuticals Rigel Pharmaceuticals Crescent Biopharma XOMA Royalty Vanda Pharmaceuticals Verastem Codexis Agenus (NASDAQ:AGEN) and Myriad Genetics (NASDAQ:MYGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings. Which has more risk & volatility, AGEN or MYGN? Agenus has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.91, indicating that its share price is 91% more volatile than the S&P 500. Do insiders & institutionals hold more shares of AGEN or MYGN? 61.5% of Agenus shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 5.5% of Agenus shares are owned by insiders. Comparatively, 2.4% of Myriad Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer AGEN or MYGN? In the previous week, Agenus had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 2 mentions for Agenus and 1 mentions for Myriad Genetics. Agenus' average media sentiment score of 0.51 beat Myriad Genetics' score of 0.00 indicating that Agenus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agenus 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer AGEN or MYGN? Agenus presently has a consensus price target of $14.00, suggesting a potential upside of 136.09%. Myriad Genetics has a consensus price target of $14.38, suggesting a potential upside of 156.87%. Given Myriad Genetics' higher possible upside, analysts clearly believe Myriad Genetics is more favorable than Agenus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agenus 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Myriad Genetics 2 Sell rating(s) 10 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.13 Is AGEN or MYGN more profitable? Myriad Genetics has a net margin of -12.20% compared to Agenus' net margin of -196.12%. Agenus' return on equity of 0.00% beat Myriad Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Agenus-196.12% N/A -82.33% Myriad Genetics -12.20%-4.95%-3.39% Which has preferable valuation & earnings, AGEN or MYGN? Myriad Genetics has higher revenue and earnings than Agenus. Myriad Genetics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgenus$103.46M1.57-$227.21M-$8.67-0.68Myriad Genetics$837.60M0.62-$127.30M-$1.12-5.00 SummaryMyriad Genetics beats Agenus on 9 of the 16 factors compared between the two stocks. Get Agenus News Delivered to You Automatically Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGEN vs. The Competition Export to ExcelMetricAgenusMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$166.42M$2.89B$5.56B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-0.6821.7127.6620.25Price / Sales1.57281.81415.41118.18Price / CashN/A42.7336.8958.07Price / Book-0.457.518.035.67Net Income-$227.21M-$55.14M$3.18B$249.21M7 Day Performance24.58%4.61%2.93%3.27%1 Month Performance14.92%4.72%3.75%5.55%1 Year Performance-60.81%5.92%35.20%21.08% Agenus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGENAgenus4.2746 of 5 stars$5.93+7.6%$14.00+136.1%-59.2%$166.42M$103.46M-0.68440MYGNMyriad Genetics4.1659 of 5 stars$5.31+1.1%$14.38+170.9%-77.6%$489.48M$837.60M-4.742,700ZBIOZenas BioPharma1.2241 of 5 stars$9.69+1.1%$36.67+278.4%N/A$405.37M$15M-2.73N/APositive NewsEBSEmergent Biosolutions4.327 of 5 stars$6.38+0.5%$14.33+124.7%-7.3%$346.31M$1.04B-2.352,420LXRXLexicon Pharmaceuticals2.5175 of 5 stars$0.95+15.2%$3.67+287.7%-45.2%$341.86M$31.08M-1.85140RIGLRigel Pharmaceuticals2.4401 of 5 stars$18.73-3.9%$36.40+94.3%+144.7%$334.71M$179.28M9.05160CBIOCrescent Biopharma3.3099 of 5 stars$16.14+1.5%$25.00+54.9%N/A$315.54M$10K-0.3526News CoverageHigh Trading VolumeXOMAXOMA Royalty4.3232 of 5 stars$25.20-8.3%$69.50+175.8%+2.1%$301.64M$28.49M-21.9110High Trading VolumeVNDAVanda Pharmaceuticals4.412 of 5 stars$4.72-1.3%$16.50+249.6%-6.8%$278.15M$198.77M-6.29290VSTMVerastem2.6497 of 5 stars$4.15flat$13.38+222.3%+61.9%$228.04M$10K-1.3050CDXSCodexis2.9472 of 5 stars$2.44+2.1%$11.00+350.8%-4.2%$202.15M$59.35M-2.46250Positive News Related Companies and Tools Related Companies Myriad Genetics Alternatives Zenas BioPharma Alternatives Emergent Biosolutions Alternatives Lexicon Pharmaceuticals Alternatives Rigel Pharmaceuticals Alternatives Crescent Biopharma Alternatives XOMA Royalty Alternatives Vanda Pharmaceuticals Alternatives Verastem Alternatives Codexis Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AGEN) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agenus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agenus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGEN Stock Alerts